PCOS Is Now PMOS. Functional Medicine Was Already Halfway There.  

Big news out of the European Congress of Endocrinology this month: after more than 90 years, polycystic ovary syndrome has a new name. 

Say hello to PMOS, Polyendocrine Metabolic Ovarian Syndrome. The change was published in The Lancet on May 12, 2026, capping a 14-year global consensus process led by Monash University, the AE-PCOS Society, and the UK charity Verity, with 56 patient and professional organizations signed on (the Endocrine Society among them). 

Here's the thing. If you practice functional medicine, this probably reads less like news and more like a long-overdue correction. You have been treating this as a whole-body endocrine and metabolic condition for years, looking at insulin, the adrenals, thyroid, inflammation, and androgen metabolism together, not in isolation. The new name finally catches the official terminology up to how you already work. 

So let's get into what changed and what it means for the way you test and treat. 

A PMOS workup is strongest when hormone, metabolic, thyroid, and inflammatory markers are interpreted together. Access Labs offers testing options that can help practitioners build a more complete view of endocrine and metabolic patterns without turning the lab process into a scavenger hunt. 

 Key Takeaways  

• PCOS has been officially renamed PMOS (Polyendocrine Metabolic Ovarian Syndrome) as of May 2026, with a three-year window before the change is fully locked in.
• The “cysts” the old name fixated on were never cysts. They are arrested follicles, and plenty of patients do not have them at all.
• The new name puts hormones and metabolism front and center — which is how root-cause practitioners have approached this condition all along. 

Why drop the “C”? 

Because the “cysts” were never cysts. 

That's the short version, and it matters. The small structures that gave PCOS its name, the ones two Chicago surgeons described back in 1935, turned out to be arrested follicles. Immature eggs that stopped developing. Not pathological growths, not something that needs surgery, and not even present in every patient. A meaningful share of people who meet full diagnostic criteria show no sign of them on ultrasound. 

Professor Helena Teede, the Monash endocrinologist who led the renaming, put it plainly in the Endocrine Society's announcement: “There is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated.” 

So the “C” had to go. What replaced it does real work. Polyendocrine names the adrenal, thyroid, ovarian, and pancreatic signaling that all sit inside this condition. Metabolic names the part, the old name buried completely, even though as many as 85% of patients live with insulin resistance, plus elevated risk for type 2 diabetes, fatty liver, and cardiovascular disease that often outlasts their reproductive years. 

The gap the old name created 

A name shapes a workup. When the word in front of a clinician says “ovary,” the labs tend to follow. 

That's the argument Teede's team makes in their Lancet policy paper, and the numbers back it up. Around 170 million people worldwide live with this condition, roughly 1 in 8 women. Up to 70% are undiagnosed. The ones who do get a diagnosis often wait years and see multiple providers first, with metabolic screening skipped along the way. 

You know these patients. By the time they reach you, they have usually seen three or four providers and built up a stack of labs that never quite added up, a TSH one year, a fasting glucose the next, nothing ever read together. Most got sent home with a birth control prescription and little else. PMOS gives you a reason to stop testing one marker at a time and look at the whole endocrine and metabolic system in one pass. 

Building a workup that fits the new name 

A total testosterone and an FSH/LH check used to be a reasonable starting point. For PMOS, it's no longer enough on its own. 

A broader sex-steroid workup covers free testosterone in addition to total, plus SHBG, DHEA-S, androstenedione, estradiol, progesterone, and the LH:FSH ratio. Run all of them and the phenotypes become easier to tell apart. Predominantly ovarian androgen excess presents differently than a case where elevated DHEA-S points to the adrenals, and a patient who stopped oral contraceptives six months ago may show flat results across the board, which a two-marker panel can easily misread. Access Labs women's hormone panels capture all of these from a single blood draw, and the assays stay accurate at the lower androgen concentrations typical of lean PMOS, where conventional reference ranges often miss the diagnosis. 

Metabolic and inflammatory testing are the last part of the workup.  

You’ll want to order fasting insulin, HOMA-IR, a lipid panel, hs-CRP, and a full thyroid panel covering TSH, free T3, free T4, reverse T3, and antibodies.  

Of those, fasting insulin and HOMA-IR are the primary focus. HbA1c by itself often comes back normal in a patient who is already insulin-resistant. The 2023 international guideline identified that as a problem. And the 2028 PMOS update carries it forward. 

The goal is to get one requisition that covers hormones, insulin, thyroid, and inflammation for the whole body during a single patient visit.  

Treatment, with the metabolic part in focus 

Metformin remains one of the best-studied tools in the PMOS toolkit, and the evidence backs that up, running from the 2000 Nestler trial through every guideline since. 

GLP-1s are now part of the PMOS conversation, too. Researchers at the University of Colorado Anschutz Medical Campus are studying semaglutide in adolescents and adults with PMOS, with a close look at menstrual frequency and glucose metabolism.  

Practitioners are already prescribing these medications off-label in some cases, but access is messy. Insurance coverage is inconsistent, and the out-of-pocket cost can be a real barrier. 

On the integrative side, the tools you already use are still needed, including inositol (myo- and D-chiro-inositol- in a 40:1 ratio), N-acetylcysteine, berberine, and targeted repletion of vitamin D, magnesium, and omega-3s.  

They work best sequenced against a nutrition, sleep, and stress plan. PMOS just makes the case for treating the entire system. 

What to do during the transition 

PCOS and PMOS will be used interchangeably until 2028, when the ICD update and the next international guideline finish the handoff. A few things worth doing before then. 

Update your intake forms and EHR templates to PMOS, but keep PCOS visible as an alias that's still the term patients are typing into search bars.  

Build one lab requisition that targets hormones, insulin, and thyroid together. This way, you avoid spreading them across visits. And talk to your patients about the change directly. They are going to see the headlines. A two-minute explanation of why the name changed from “ovary” to “endocrine and metabolic” goes a long way toward resetting what they expect from care. 

The renaming is not a new protocol or a new science. It is the official language, finally describing what functional practitioners have been treating for a long time before the consortium met. PMOS removes the decades-long slowdown in integrated care and makes room for the kind of full-system workup these patients have needed since 1935. 

Access Labs women's hormone and metabolic panels bring sex steroids, fasting insulin, thyroid, and inflammatory markers onto one requisition, with the assay sensitivities these phenotypes require. Browse the full test menu to plan your next order. 

Disclaimer: Content on the Access Labs blog is for informational purposes only and reflects the views of individual contributors, not necessarily those of Access Medical Labs. We do not endorse specific treatments, products, or protocols. This content is not a substitute for professional medical advice. Always consult a qualified healthcare provider regarding any medical concerns.

 

About Access:

Access is the nation’s premier specialty diagnostic lab. We offer a broad menu of testing from blood, saliva, urine & swab samples. We perform all of your tests in our 25,000 sq. ft. ultra-automated facility in Jupiter, Florida & provide results within 24hrs. Since 2003, we continuously strive to innovate, inspire, and improve solutions for physicians by providing an exceptional personalized experience with the most accurate testing.

Feel free to contact our specialist to find out more about prices and services. We are always ready to answer your questions: sales@accesslabs.com